BR112021020751A2 - Método para determinar o nível de inibidor funcional de c1-esterase (fc1-inh) em uma amostra - Google Patents

Método para determinar o nível de inibidor funcional de c1-esterase (fc1-inh) em uma amostra

Info

Publication number
BR112021020751A2
BR112021020751A2 BR112021020751A BR112021020751A BR112021020751A2 BR 112021020751 A2 BR112021020751 A2 BR 112021020751A2 BR 112021020751 A BR112021020751 A BR 112021020751A BR 112021020751 A BR112021020751 A BR 112021020751A BR 112021020751 A2 BR112021020751 A2 BR 112021020751A2
Authority
BR
Brazil
Prior art keywords
inh
level
sample
functional
determining
Prior art date
Application number
BR112021020751A
Other languages
English (en)
Inventor
Guodong Zhang
Jiang Wu
Sethu Chockalingam Priya
Yongquan Lai
Zhiwei Zhou
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112021020751A2 publication Critical patent/BR112021020751A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21042Complement subcomponent C1s (3.4.21.42)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811Serine protease (E.C. 3.4.21) inhibitors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • G01N2333/96441Serine endopeptidases (3.4.21) with definite EC number
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

método para determinar o nível de inibidor funcional de c1-esterase (fc1-inh) em uma amostra. métodos para quantificação de fc1-inh a partir de mancha de sangue seco são fornecidos neste documento. tais métodos podem compreender manchar e secar uma amostra de sangue em um membro de suporte, extrair proteína da amostra de sangue seco e medir o nível de fc1-inh nas proteínas extraídas.
BR112021020751A 2019-04-16 2020-04-15 Método para determinar o nível de inibidor funcional de c1-esterase (fc1-inh) em uma amostra BR112021020751A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962834461P 2019-04-16 2019-04-16
US201962932011P 2019-11-07 2019-11-07
PCT/US2020/028205 WO2020214638A1 (en) 2019-04-16 2020-04-15 Methods for quantitation of functional c1 esterase inhibitor (fc1-inh)

Publications (1)

Publication Number Publication Date
BR112021020751A2 true BR112021020751A2 (pt) 2021-12-14

Family

ID=70617205

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020751A BR112021020751A2 (pt) 2019-04-16 2020-04-15 Método para determinar o nível de inibidor funcional de c1-esterase (fc1-inh) em uma amostra

Country Status (13)

Country Link
US (1) US11754570B2 (pt)
EP (1) EP3956667B1 (pt)
JP (1) JP2022529265A (pt)
KR (1) KR20210153097A (pt)
CN (1) CN114402200A (pt)
AU (1) AU2020258869A1 (pt)
BR (1) BR112021020751A2 (pt)
CA (1) CA3137014A1 (pt)
CO (1) CO2021014146A2 (pt)
IL (1) IL287294A (pt)
MX (1) MX2021012581A (pt)
TW (1) TW202104900A (pt)
WO (1) WO2020214638A1 (pt)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE15387T1 (de) 1980-09-30 1985-09-15 Cornell Res Foundation Inc Verfahren zum bestimmen von enzym-inhibitorkomplexen.
US4849353A (en) 1980-09-30 1989-07-18 Cornell Research Foundation, Inc. Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof
JPH0754323B2 (ja) 1988-10-17 1995-06-07 三洋化成工業株式会社 免疫測定法および免疫測定試薬
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CN1057607C (zh) 1995-12-04 2000-10-18 广州市博普生物技术有限公司 一种双功能层析材料及制备方法和应用
JP2003505678A (ja) 1999-07-23 2003-02-12 ザ スクリップス リサーチ インスティテュート 全血の凝固因子活性を測定する方法
DE122011000002I1 (de) 2000-01-31 2011-05-05 Pharming Intellectual Pty Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
US6905816B2 (en) 2000-11-27 2005-06-14 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
AU2002230523A1 (en) 2000-11-27 2002-06-03 Genevention L.L.C. Clinically intelligent diagnostic devices and methods
EP2090589A1 (en) 2002-02-07 2009-08-19 Dyax Corp. Albumin-fused Kunitz domain peptides
CA2895272A1 (en) 2003-07-17 2005-02-03 Pacific Edge Biotechnology, Ltd. Markers for detection of gastric cancer
WO2005098446A2 (en) 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
EP1954822A1 (en) 2005-11-23 2008-08-13 Georg Dewald Detection and treatment of drug associated angioedema
US7923240B2 (en) 2006-03-31 2011-04-12 Intel Corporation Photo-activated field effect transistor for bioanalyte detection
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
NZ578164A (en) 2007-01-16 2011-12-22 Musc Found For Res Dev Compositions and methods for diagnosing, treating, and preventing prostate conditions
WO2008091692A2 (en) 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
WO2008098720A1 (en) 2007-02-12 2008-08-21 Csl Behring Gmbh Therapeutic application of kazal-type serine protease inhibitors
EP2356457B1 (en) 2008-10-13 2018-05-16 Xeptagen SPA Method for the preparation of immunoconjugates and use thereof
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8883153B2 (en) 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
US20110140706A1 (en) 2009-05-07 2011-06-16 Groves John T Particle-Based Electrostatic Sensing and Detection
CA3021759A1 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
US8816055B2 (en) 2011-01-06 2014-08-26 Dyax Corp. Plasma kallikrein binding proteins
LT2946206T (lt) 2013-01-20 2019-04-25 Dyax Corp. Pkal sąlygotų sutrikimų vertinimas, tyrimas ir gydymas
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
US20200340987A1 (en) 2019-02-21 2020-10-29 Dyax Corp. Lateral flow immunoassay for measuring functional c1-esterase inhibitor (c1-inh) in plasma samples

Also Published As

Publication number Publication date
IL287294A (en) 2021-12-01
AU2020258869A1 (en) 2021-11-25
MX2021012581A (es) 2021-12-10
US11754570B2 (en) 2023-09-12
JP2022529265A (ja) 2022-06-20
EP3956667B1 (en) 2024-03-13
EP3956667A1 (en) 2022-02-23
TW202104900A (zh) 2021-02-01
EP3956667C0 (en) 2024-03-13
WO2020214638A1 (en) 2020-10-22
US20200348311A1 (en) 2020-11-05
CO2021014146A2 (es) 2021-10-29
CA3137014A1 (en) 2020-10-22
CN114402200A (zh) 2022-04-26
KR20210153097A (ko) 2021-12-16

Similar Documents

Publication Publication Date Title
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
BR112018074853A2 (pt) métodos para detectar a presença de pelo menos um genogrupo de norovírus em uma amostra de fezes e para selecionar um paciente que sofre de gastroenterite aguda, e, kit
BR112012009481A2 (pt) método e dispositivo para detectar uma pluralidade de alvos em uma amostra biológica, e, kit para detectar uma pluralidade de alvos múltiplos em uma amostra biológica
BR112016019740A2 (pt) monitoramento do estado de inflamação
Brioschi et al. Proteomic analysis of endothelial cell secretome: a means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors
RU2009129185A (ru) Способы и мишени для идентификации соединений для регуляции риновирусной инфекции
JP2019507341A5 (pt)
CA2798517A1 (en) Systems and methods of detecting and demonstrating hair damage via evaluation of protein fragments
DK1175511T3 (da) Fremgangsmåde og testsæt til opsamling og opbevaring af biologiske pröver
DK2185937T4 (da) Fremgangsmåde til at bestemme sepsis hos mennesker
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
BR112019005172A2 (pt) método e kit para analisar uma amostra
FI3509624T3 (fi) Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi
BR112021020751A2 (pt) Método para determinar o nível de inibidor funcional de c1-esterase (fc1-inh) em uma amostra
BR112016015537A2 (pt) métodos e kits para detectar a presença de sequência polinucleotídea da e. histolytica em amostra
AR105439A1 (es) Procedimientos de purificación de un virus producido in vitro y ensayo de eliminación del virus
DK3983783T3 (da) Fremgangsmåde til påvisning af skatol i en fedtvævsprøve fra svin
UY38519A (es) Composiciones y procedimientos para la detección de ácido nucleico de especies de plasmodium
ATE354095T1 (de) Verfahren zur detektion von prp unter verwendung ein makrozyklischen ligand
MX2020001818A (es) Isoelectroenfoque capilar con imagenes para analizar variantes de proteina en una matriz de muestra.
WO2023003647A9 (en) Methods for determining variant frequency and monitoring disease progression
BR112019005179A2 (pt) método e kit para analisar uma amostra
PE20191707A1 (es) Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1
AR118701A1 (es) Métodos para cuantificar el inhibidor de esterasa c1 funcional (fc1-inh)